2019
April 26, 2019 - Karuna Therapeutics Files Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering
April 1, 2019 - Karuna Completes $80 Million Series B Financing
March 18, 2019 - Karuna Announces $68 Million Series B Financing
March 13, 2019 - Karuna Bolsters Research and Development Team
March 5, 2019 - Karuna Strengthens Senior Leadership Team with Appointment of Chief Financial Officer
January 11, 2019 - A Boston biotech takes on a challenge most companies have avoided: making a better schizophrenia drug
2018
December 10, 2018 - Karuna Pharmaceuticals to Present Results of KarXT Phase 1 Study at American College of Neuropsychopharmacology Annual Meeting
October 17, 2018 - Karuna Appoints Jeff Jonas, M.D., to Board of Directors
October 15, 2018 - Karuna Announces First Patient Dosed in Phase 2 Study of Lead Product Candidate KarXT for the Treatment of Schizophrenia
August 15, 2018 - Karuna Appoints Seasoned Biopharma Veteran Steven Paul, M.D., as Chief Executive Officer
August 2, 2018 - Karuna Completes $42 Million Series A Financing Round to Advance Selective Muscarinic Receptor Agonist Program into Phase 2 Study
June 19, 2018 - Karuna Receives $8 Million Wellcome Trust Award to Advance First-in-Class Phase 2 Clinical Program in Schizophrenia
2017
May 19, 2017 — Karuna Pharmaceuticals to Present KarXT Tolerability Proof-of-Concept Data for KarXT, A Novel Antipsychotic Agent Targeting the Muscarinic Receptors, at Two Upcoming Medical Meetings
2016
December 15, 2016 — Karuna Pharmaceuticals and PureTech Health Announce Positive Results from Tolerability Proof-of-Concept Study of KarXT, Being Developed for Schizophrenia and Alzheimer's
December 5, 2016 — ACNP 55th Annual Meeting Presentation: Xanomeline Plus Trospium: A Novel Strategy to Enhance Pro-Muscarinic Efficacy and Mitigate Peripheral Side Effects
September 12, 2016 — Karuna Doses First Subject in Tolerability Proof-of-Concept Study of Lead Product Candidate
July 29, 2016 — Karuna Pharmaceuticals Appoints Atul Pande, M.D., to Board of Directors
2015
August 5, 2015 — Karuna Receives Wellcome Trust Award to Advance Innovative Clinical Stage Product Candidate for the Treatment of Schizophrenia
